Laurie Toich, Assistant Editor

Top healthcare news from across the healthcare landscape.

The FDA approved nusinersen (Spinraza) for the treatment of patients with spinal muscular atrophy.

The most popular articles of the year from the American Journal of Pharmacy Benefits.

A new survey reveals patients are concerned about costs, but largely unaware of health plan benefits.

Smaller co-payments for prescription drugs leaves individuals less likely to visit the hospital.

Sage Therapeutics is beginning studies to explore the use of SAGE-217 in patients with Parkinson’s disease and essential tremors.

This year's top drug approvals.

Billions wasted each year from lack of adherence to prescription medications.

Myeloproliferative neoplasms may negatively affect the physical and mental health of patients.

Targeting the KRAS mutation was found successful in a patient with metastatic colorectal cancer.

Treatment with an intereleukin-1 receptor antagonist may prevent stroke damage.

From 2003 to 2013, an average of 37 healthcare professionals died from drug-related causes in Australia.

This year's top oncology articles.

Sage Therapeutics plans to work with the FDA to expedite the approval of a drug for postpartum depression.

Patients who switched to Ultibro Breezhaler had an increase in lung function.

Platypus and echidna venom contains a stable form of a hormone that could be used to improve diabetes treatment.

A new report indicates that additional efforts may be needed to control antibiotic resistance in Europe.

This year's top articles about the Affordable Care Act.

Reovirus could treat liver diseases such as hepatitis C virus and primary liver cancer.

This year's top news regarding pharmacy benefit managers.

Medical marijuana could potentially be used to treat drug addiction and certain mental health conditions.

This year's top 10 top articles about diabetes.

Out-of-pocket costs may prevent patients with chronic illnesses from purchasing some Affordable Care Act plans.

Treatment with everolimus reduced seizure incidence up to 39.6%.

HCV patients without cirrhosis achieved SVR after 8 weeks of treatment with glecaprevir/pibrentasvir.

HCV patients without cirrhosis achieved SVR after 8 weeks of treatment with glecaprevir/pibrentasvir.

Clonidine topical gel was not more effective than placebo in reducing pain from diabetic neuropathy.

A combination of oxaprozin and salbutamol would provide patients with an easier treatment regimen.

Top news of the day from across the healthcare landscape.

After 4 weeks of moderate exercise, rat models with diabetes had improved memory function.